Resource Type

Journal Article 510

Conference Videos 8

Year

2024 1

2023 35

2022 44

2021 53

2020 32

2019 48

2018 30

2017 36

2016 22

2015 26

2014 23

2013 26

2012 19

2011 21

2010 15

2009 30

2008 13

2007 14

2006 2

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 9

targeted therapy 8

cancer 7

cancer therapy 7

solar cell 6

therapy 6

SARS-CoV-2 5

gene therapy 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

lung cancer 5

stem cell 5

COVID-19 4

cell proliferation 4

control 4

hepatocellular carcinoma 4

immune checkpoint inhibitor 4

microbial fuel cell 4

open ︾

Search scope:

排序： Display mode:

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity

Chuanfeng Wu, Cynthia E. Dunbar

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 356-371 doi: 10.1007/s11684-011-0159-1

Abstract: Virus-based vectors are widely used in hematopoietic stem cell (HSC) gene therapy, and have the abilityTo date, HSC gene therapy has been successfully employed in the clinic for improving clinical outcomesHowever, adverse events were observed during some of these HSC gene therapy clinical trials, linked tobasis of vector-mediated genotoxicity, with the aim of developing safer vectors and lower-risk gene therapyintroduce newly-developed approaches for minimizing genotoxicity as a way to further move HSC gene therapy

Keywords： gene therapy     hematopoietic stem cells     insertional mutagenesis     genotoxicity     induced pluripotent stem cell    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltratingCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughshematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

Cell therapy for the treatment of reproductive diseases and infertility: an overview from the mechanism

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 827-858 doi: 10.1007/s11684-022-0948-8

Abstract: been used to manage ovarian and uterine disorders, and each technique presents a novel method for the therapy

Keywords： infertility     stem cell therapy     mesenchymal stem cells     pluripotent stem cells    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: In general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)The early diagnosis and therapy of lung cancer still presents a big challenge because validated screeningTherefore, this information may be applied for early cancer detection, classification, novel targeted therapyRecent clinical data have revealed that targeted therapy might be the second-line therapy as an alternativewith biomarkers to match targeted agents so that we can further identify effectiveness of targeted therapy

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: achieved complete remission after receiving the CD19 CAR-T cell therapy.therapy.Nonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such asTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapiesThis study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Chemical transdifferentiation: closer to regenerative medicine

Aining Xu,Lin Cheng

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 152-165 doi: 10.1007/s11684-016-0445-z

Abstract:

Cell transdifferentiation, which directly switches one type of differentiated cells into another celltype, is more advantageous than cell reprogramming to generate pluripotent cells and differentiate themdevelopments in the research of small molecules in promoting cell conversion.Particularly, we focus on the complete chemical compound-induced cell transdifferentiation, which iscloser to the clinical translation in cell therapy.

Keywords： cell therapy     cell transdifferentiation     chemical compounds     small molecules     tissue regeneration    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapyand other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T celltherapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords： B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

HTML PDF Collect

The regulatory sciences for stem cell-based medicinal products

Bao-Zhu Yuan,Junzhi Wang

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 190-200 doi: 10.1007/s11684-014-0323-5

Abstract:

Over the past few years, several new achievements have been made from stem cell studies, many of whichMoreover, some stem cell-based products have been approved for marketing by different national regulatoryHowever, many critical issues associated mainly with incomplete understanding of stem cell biology andIn this review, we summarize some new achievements in stem cell studies, especially the preclinical andabreast of evolvement of stem cell sciences and technologies.

Keywords： stem cell-based medicinal products (SCMPs)     stem cell therapy (SCT)     safety     effectiveness     standards     guidelines    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis.Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallytherapy.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

NADPH oxidase and reactive oxygen species as signaling molecules in carcinogenesis

Gang WANG

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 1-7 doi: 10.1007/s11684-009-0018-5

Abstract: Reactive oxygen species (ROS) are small molecule metabolites of oxygen that are prone to participate in redox reactions their high reactivity. Intracellular ROS could be generated in reduced nicotinamide-adenine dinucleotidephosphate (NADPH) oxidase-dependent and/or NADPH oxidase-independent manners. Physiologically, ROS are involved in many signaling cascades that contribute to normal processes. One classical example is that ROS derived from the NADPH oxidase and released in neurotrophils are able to digest invading bacteria. Excessive ROS, however, contribute to pathogenesis of various human diseases including cancer, aging, dimentia and hypertension. As signaling messengers, ROS are able to oxidize many targets such as DNA, proteins and lipids, which may be linked with tumor growth, invasion or metastasis. The present review summarizes recent advances in our comprehensive understanding of ROS-linked signaling pathways in regulation of tumor growth, invasion and metastasis, and focuses on the role of the NADPH oxidase-derived ROS in cancer pathogenesis.

Keywords： free radicals     tumor     phox     cell proliferation     cancer therapy    

HTML PDF Collect

Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 784-798 doi: 10.1007/s11684-021-0911-0

Abstract: interference approaches revealed that the loss of GNAQ/11 palmitoylation substantially affected tumor cellImportantly, the palmitoylation-deficient oncogenic GNAQ/11 failed to rescue the cell death initiatedoncogenes in UM cells, which are much more dependent on Gαq/11 signaling for cell

Keywords： uveal melanoma     mutant GNAQ/11     palmitoylation     BCL2     combination target therapy    

HTML PDF Collect

Cell Therapy: Pharmacological Intervention Enters a Third Era

Wei He

Engineering 2019, Volume 5, Issue 1,   Pages 5-9 doi: 10.1016/j.eng.2018.11.017

HTML PDF Collect

Title Author Date Type Operation

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity

Chuanfeng Wu, Cynthia E. Dunbar

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

Cell therapy for the treatment of reproductive diseases and infertility: an overview from the mechanism

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

Chemical transdifferentiation: closer to regenerative medicine

Aining Xu,Lin Cheng

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

Gu Zhen: Cell Loading Device for Cell Therapy (2022-7-24)

27 Jul 2022

Conference Videos

The regulatory sciences for stem cell-based medicinal products

Bao-Zhu Yuan,Junzhi Wang

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

NADPH oxidase and reactive oxygen species as signaling molecules in carcinogenesis

Gang WANG

Journal Article

Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal

Journal Article

Cell Therapy: Pharmacological Intervention Enters a Third Era

Wei He

Journal Article